Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 2
2001 1
2002 5
2003 3
2004 3
2005 4
2006 7
2007 14
2008 18
2009 20
2010 21
2011 30
2012 42
2013 53
2014 42
2015 43
2016 33
2017 37
2018 35
2019 42
2020 44
Text availability
Article attribute
Article type
Publication date

Search Results

455 results
Results by year
Filters applied: . Clear all
Page 1
Progress in gene therapy using oncolytic vaccinia virus as vectors.
Yang X, Huang B, Deng L, Hu Z. Yang X, et al. J Cancer Res Clin Oncol. 2018 Dec;144(12):2433-2440. doi: 10.1007/s00432-018-2762-x. Epub 2018 Oct 6. J Cancer Res Clin Oncol. 2018. PMID: 30293118 Review.
Vaccinia virus can selectively replicate and propagate productively in tumor cells, resulting in oncolysis. In addition, rapid viral particle production, wide host range, large genome size (approximately 200 kb), and safe handling render vaccinia virus
Vaccinia virus can selectively replicate and propagate productively in tumor cells, resulting in oncolysis. In addition, rapid
Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H, Ino Y, Todo T. Fukuhara H, et al. Cancer Sci. 2016 Oct;107(10):1373-1379. doi: 10.1111/cas.13027. Epub 2016 Sep 9. Cancer Sci. 2016. PMID: 27486853 Free PMC article. Review.
T-Vec (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1 (HSV-1) armed with GM-CSF, was recently approved as the first oncolytic virus drug in the USA and Europe. ...Other oncolytic viruses that are closing in …
T-Vec (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1 (HSV-1) armed with GM-CSF, was rec …
Virus, Oncolytic Virus and Human Prostate Cancer.
Liu GB, Zhao L, Zhang L, Zhao KN. Liu GB, et al. Curr Cancer Drug Targets. 2017;17(6):522-533. doi: 10.2174/1568009616666161216095308. Curr Cancer Drug Targets. 2017. PMID: 27993115 Review.
METHOD: In this review study, we first discuss the controversy of the contribution of virus infection to PCa, and subsequently summarize the development of oncolytic virotherapy for PCa in the past several years. ...Oncolytic viruses can be genetically engine …
METHOD: In this review study, we first discuss the controversy of the contribution of virus infection to PCa, and subsequently summar …
Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models.
Cecil A, Gentschev I, Adelfinger M, Dandekar T, Szalay AA. Cecil A, et al. Bioengineered. 2019 Dec;10(1):190-196. doi: 10.1080/21655979.2019.1622220. Bioengineered. 2019. PMID: 31142183 Free PMC article.
Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a promising approach for cancer therapy. Recently, we showed that the oncolytic vaccinia virus GLV-1h68 has a therapeutic potential in treating human prostate and hepa …
Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a promising approach for cancer therapy. Recentl …
Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.
Draganov DD, Santidrian AF, Minev I, Nguyen D, Kilinc MO, Petrov I, Vyalkova A, Lander E, Berman M, Minev B, Szalay AA. Draganov DD, et al. J Transl Med. 2019 Mar 27;17(1):100. doi: 10.1186/s12967-019-1829-z. J Transl Med. 2019. PMID: 30917829 Free PMC article.
BACKGROUND: Previous studies have identified IFNγ as an important early barrier to oncolytic viruses including vaccinia. The existing innate and adaptive immune barriers restricting oncolytic virotherapy, however, can be overcome using autologous or allogenei …
BACKGROUND: Previous studies have identified IFNγ as an important early barrier to oncolytic viruses including vaccinia. The e …
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Guo ZS, et al. J Immunother Cancer. 2019 Jan 9;7(1):6. doi: 10.1186/s40425-018-0495-7. J Immunother Cancer. 2019. PMID: 30626434 Free PMC article. Review.
Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with potential to provide greater clinical benefit to patients with advanced-stage cancer. In particular, recombinant vaccinia viruses (VV) hold great promise as interventional agents. In …
Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with potential to provide greater clinical benefit to …
Vaccinia virus evasion of regulated cell death.
Veyer DL, Carrara G, Maluquer de Motes C, Smith GL. Veyer DL, et al. Immunol Lett. 2017 Jun;186:68-80. doi: 10.1016/j.imlet.2017.03.015. Epub 2017 Mar 31. Immunol Lett. 2017. PMID: 28366525 Free article. Review.
Vaccinia virus (VACV), a poxvirus and the vaccine used to eradicate smallpox, encodes multiple proteins that interfere with apoptotic, necroptotic and pyroptotic signalling. ...Studying the mechanisms evolved by VACV to counteract host programmed cell death has impl
Vaccinia virus (VACV), a poxvirus and the vaccine used to eradicate smallpox, encodes multiple proteins that interfere with ap
The emerging role of oncolytic virus therapy against cancer.
Russell L, Peng KW. Russell L, et al. Chin Clin Oncol. 2018 Apr;7(2):16. doi: 10.21037/cco.2018.04.04. Chin Clin Oncol. 2018. PMID: 29764161 Free PMC article. Review.
Three oncolytic viruses (OVs), an echovirus, an adenovirus, and a herpes simplex-1 virus, have passed governmental regulatory approval in Latvia, China, and the USA and EU. Numerous other recombinant viruses from diverse families are in clinical testing in cancer pa …
Three oncolytic viruses (OVs), an echovirus, an adenovirus, and a herpes simplex-1 virus, have passed governmental regulatory …
Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis.
Lauer UM, Schell M, Beil J, Berchtold S, Koppenhöfer U, Glatzle J, Königsrainer A, Möhle R, Nann D, Fend F, Pfannenberg C, Bitzer M, Malek NP. Lauer UM, et al. Clin Cancer Res. 2018 Sep 15;24(18):4388-4398. doi: 10.1158/1078-0432.CCR-18-0244. Epub 2018 May 17. Clin Cancer Res. 2018. PMID: 29773661 Free article. Clinical Trial.
Here, we report on a phase I study designed to assess safety, MTD, and antitumor activity of intraperitoneal administration of oncolytic vaccinia virus GL-ONC1 in advanced stage peritoneal carcinomatosis patients.Patients and Methods: GL-ONC1 was administered …
Here, we report on a phase I study designed to assess safety, MTD, and antitumor activity of intraperitoneal administration of oncolytic
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.
Foloppe J, Kempf J, Futin N, Kintz J, Cordier P, Pichon C, Findeli A, Vorburger F, Quemeneur E, Erbs P. Foloppe J, et al. Mol Ther Oncolytics. 2019 Mar 27;14:1-14. doi: 10.1016/j.omto.2019.03.005. eCollection 2019 Sep 27. Mol Ther Oncolytics. 2019. PMID: 31011628 Free PMC article.
Oncolytic vaccinia viruses are currently in clinical development. However, the safety and the tumor selectivity of these oncolytic viruses must be improved. We previously constructed a first-generation oncolytic vaccinia virus by expressi
Oncolytic vaccinia viruses are currently in clinical development. However, the safety and the tumor selectivity of these on
455 results
Jump to page
Feedback